Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in HER2-overexpressed Recurrent Stage IV Breast Cancer
NCT02418689Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in breast cancer, sponsored by Hanmi Pharmaceutical. Started Apr 2015; status: completed.
02
Drugs
poziotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02418689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418689.